







































Volume 03 Issue 12-2023 6 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

 

 

ABSTRACT 

Previous research has investigated the technological properties of the dexketoprofen trametamol substance and has 

been shown to be negative. For this reason, the article covers research on the selection, technology development of 

a complex of various auxiliary substances for the development of a capsule drug form based on the substance 

dexketoprofen trametamol. In it, the size of the capsule was determined on scientific basis, based on the scattering 

density of the substance, and encapsulated masses were prepared using various excipients. As a result of determining 

the technological properties of these compositions as well as the quality indicators of the capsules obtained, the 

optimal composition was selected and the capsule technology was developed, in which the dexketoprofen 

trametamol substance was stored. 

KEYWORDS 

Deksketoprofen trometamol, substance, capsule, technology, excipients, composition, technological properties. 

INTRODUCTION

  Research Article 

 

DEKSKETOPROFEN TRAMETAMOL CAPSULE DRUG FORM 

COMPOSITION SELECTION AND TECHNOLOGY DEVELOPMENT 
 

Submission Date: December 01, 2023, Accepted Date:  December 05, 2023,  

Published Date: December 10, 2023  

Crossref doi: https://doi.org/10.37547/ajbspi/Volume03Issue12-02 

 

 

M.K.Usmonova. 
Assistant, Tashkent Pharmaceutical Institute, Uzbekistan 

 

F.X.Maksudova. 
Associate Professor (Dsc), Tashkent Pharmaceutical Institute, Uzbekistan 

 

A.M.Usubbaev 
Associate Professor (Phd), Tashkent Pharmaceutical Institute, Uzbekistan 

 

 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://doi.org/10.37547/ajbspi/Volume03Issue12-02
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 03 Issue 12-2023 7 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Adaptation of highly effective, stable and high-quality 

medicines produced in foreign countries to the 

practice of domestic production without affecting 

their quality and, thus, partial provision of the domestic 

market of the Republic of Uzbekistan with high-quality, 

affordable and necessary medicines is one of the most 

important and urgent tasks facing pharmaceutical 

technologists. [1,2]. 

Today, capsules occupy a special place among ready-

made medicines and occupy the third place in 

pharmaceutical production after tablets and 

ampoules. [8]. 

Capsule types of medicines are the leaders among 

ready-made medicines produced on an industrial scale. 

The main reason for this is a number of advantages of 

the capsule type of medicine: accurate dosage, rapid 

action on the body, the fact that the medicinal 

substance is protected from exposure to light, 

moisture, air, its stability is ensured, the unpleasant 

smell and taste of the medicinal substance are 

disguised, dyes and easily pollinated substances can be 

used when air moves, as well as high bioefficiency, as 

well as the ability to prolong the action of the active 

substance and use it for what has control capabilities 

[4,7]. 

Many synthetic drugs have the property of tickling the 

mucous membrane of the gastrointestinal tract, and 

when taken for a long time, the wound can become a 

dressing. Also, some active substations lose their 

effect from the action of acid in gastric juice. Even in 

such cases, it is advisable to apply gelatin capsules. 

Such capsules will be intended for dissolution in the 

intestine, that is, they will not decompose under the 

action of acid from gastric juice[8]. 

Based on the results of research carried out by many 

scientists in recent years, the absence of a pressing 

process in the development of the capsule drug form 

ensures that they decompose faster than tablets and 

dragees and are absorbed into the body faster, and 

pharmacotherapeutic activity Ham manifests much 

faster [3]. 

The purpose of the study. Taking into account the 

above, the goal was set to develop a capsule drug form 

of dexketoprofen trometamol substance. 

Experience part 

Research methods and tasks. In our scientific research, 

we used the substance deksketoprofen trametamol 

(NN 42 Uz-8979-2018). This substance is a white 

crystalline powder, freely soluble in methanol and 

water, slightly soluble in chloroform and slightly 

soluble in ethanol. 

Deksketoprofen trametamol is a non-selective 

nonsteroidal anti-inflammatory drug of the 

arylpropionic acid group containing the active c-

enantiomer of racemic ketoprofen, an analgesic 

characterized by a rapid onset of action and a relatively 

short half-life. Trometamol salt ensures rapid 

dissolution and absorption, which is especially 

important in severe pain. The duration of pain relief is 

4-6 hours, the mechanism of dual action from the 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 12-2023 8 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

central and peripheral side is of particular interest to 

him, as a result of which dexketoprofen prevents the 

increase of pain, as well as the formation of  “Pain 

memory” does. [2,6,7]. 

According to the regulatory document (NN 42 Uz-

8979-2018) and with the recommendation of 

pharmacologists, the therapeutic dose of 

deksketoprofen-trametamol substance was 

determined to be equal to 36.9 mg. 

Size 8 empty capsules were used for scientific 

justification of capsule size. 

For determination of encapsulable masses and 

technological properties and quality indicators of 

capsules, such as dispersion, fraction of fractions 0.2-

0.5 mm in size, dispersion density, angle of natural 

deviation, disintegration and residual moisture Uz DF 

Volume 1 and DF was performed according to the 

methods defined in Edition XIV (RF). Tests were 

performed five times and average values were 

calculated. [5,9,10]. 

Research results and their discussion. First of all, it was 

necessary to scientifically justify the size of the capsule. 

For this, the volume occupied by deksketoprofen 

trametamol substance based on the dispersion density 

indicator is calculated.  

The obtained results are presented in Table 1. 

Table 1. 

Results of choosing the size of the capsule that stored deksketoprofen trametamol 

Capsule size 5 4 3 2 1 0 00 000 

The average volume of the 

capsule, sm3 

0,13 0,21 0,30 0,37 0,5 0,68 0,95 1,37 

The volume occupied by 

the therapeutic dose of 

deksketoprofen 

trametamol substance, % 

95% 45% 32% 26% 19% 14% 10% 7% 

Empty volume, % 5% 55% 68% 74% 81% 86% 90% 93% 

The results presented in Table 1 showed that the 

therapeutic dose of deksketoprofen trametamol 

substance is small, so the occupied volume is also 

small. For this reason, it was determined that it is 

appropriate to use 3-dimensional capsules in the 

development of the capsule drug form. 

When choosing the composition of the capsule 

containing deksketoprofen trametamol, from auxiliary 

substances that are widely used in the pharmaceutical 

industry today: corn starch as a filler, microcrystalline 

cellulose, NaKMS, maltose, isomalt, dextrose, 

maltodextrin, silicon dioxide, potato starch, 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 12-2023 9 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

magnesium stearate from antifriction agents, stearate, 

talc, calcium stearate, purified water as a wetting 

agent, alcohols of various concentrations were used, 

and capsule masses were prepared by wet granulation 

method. 

When creating a capsule drug form on the basis of 

deksketoprofen trametamol, methods presented in 

the literature were used to study its technological 

properties of compositions in volatility, volatility 

density, natural deviation angle, fragmentation, 

fraction content from 0.2 to 0.5 mm in size and residual 

moisture. 

In total, about 15 compositions were prepared, and 

from them the bulk compositions with good mass 

dressing and positive technological bearings are 

presented in Table 2.

 

Table 2. 

Components of recommendations and technological views for a capsule containing the substance deksketoprofen 

trametamol 

 

 

 

 

 

Compositions 

 

Technological properties of encapsulated masses 

 
 

 

scattering, 

10-3 kg/s 

 

 

 

scattering 

density, 

kg/m3 

 

 

natural 

deviation 

angle, 

degree 

 

size 

Percentage of 

fractions 0.2-

0.5 mm , % 

 

 

residual 

moisture, 

% 

 

 

moment of 

Decay 

compound-1 4.43±0,78 0,442±20,62 31,09±1,05 80,32±1,65 2,03±0,22 7,75±1,13 

compound-2 5,79±1,09 0,578±16,47 32,04±1,66 92,14±1,38 2,05±0,33 6,55±1,45 

compound-3 3,78±0,68 0,622±17,83 35,22±1,70 92,32±1,91 2,02±0,20 6,07±0,58 

compound-4 5,93 ±0,92 0,785±20,19  32,5±1,52 97,41±1,02 1,92±0,42 5,10±0.21 

compound-5 4,08±1,29 0,698±18,20 30,02±1,28 88,8±0,78 1,8±0,21 5.07±0,54 

According to the data presented in the literature, the 

volatility and scattering density of the encapsulated 

mass depends on the percentage of fractions from 0.2 

to 0.5 mm relative to the total amount, and it is 

recommended that this figure is not 85% less. 1 in the 

mixture obtained by composition, the amount of this 

fraction was less than 85%, which was 80.32±1.65%. At 

the same time 2, 3, 4 and 5 mixtures according to the 

composition the fraction amount given above 

92,14±1,38%, 92,32±1,91%, 97,41±1,02 and 88.8±0.78%. 

The proof of the cited opinion was demonstrated in the 

results of the determination of volatility: with the 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 12-2023 10 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

proportion of fractions of 0.2-0.5 mm greater than 85%, 

the volatility was also higher, for example 4.43±0,78 10-

3 kg/s (1-composition), 5,93 ±0,92 10-3 kg/s (4-

composition), 4,08±1,29 10-3 kg/s (5-composition). 

It was the scattering density of compositions 3, 4 and 5 

that also showed high performance and, respectively 

0,622±17,83 kg/m3, 0,785±20,19 kg/m3 va 0,698±18,20 

kg/m3 was equal. 

The angle of natural deviation was positive in all 

analyzed compositions and this indicator was from 

30.02±1.28 degrees to 32.5±1.52 degrees. 

According to UzR DF and DF XIV edition (RF), the 

disintegration of granules should not exceed 15 

minutes. All tested compositions met the requirement 

for this indicator and their disintegration time ranged 

from 5.10±0.21 minutes to 7.75±1.13 minutes, i.e. did not 

exceed the specified 15 minutes. At the same time, 

residual moisture should not exceed 5%. All the 

analyzed contents met the requirement and the 

moisture content in them was 2,03±0,22%, 2,05±0,33%, 

2,02±0,20%, It was 1.92±0.42% and 1.8±0.21%. 

Taking into account the above, the most optimal mass 

for the capsule was 2 and 4 compositions. But since the 

scattering indicator is of great importance at the time 

of filling the capsule, 4 ingredients with a high level of 

this indicator were selected. 

The obtained mass according to this composition was 

prepared according to the following technology: 

Taking into account the physico-chemical and 

technological properties of the substances, it was 

considered preferable to prepare the encapsulated 

mass by wet granulation method. For this, 

dexketoprofen, trometamol and maltose substances 

were passed through a sieve with a hole diameter of 

150 μm.Half the amount of cornstarch was added and 

mixed until a uniform mass was formed. Purified water 

was added by spraying until a moderately wet mass 

was formed. The wet mass was passed through a sieve 

with a diameter of 3000 μm and dried on a drying rack 

at a temperature of 40-500С until moderate moisture 

remained.The dried mass was passed through a sieve 

with a hole diameter of 1000 μm and mixed with the 

rest of corn starch and a mixture of calcium 

stearate.The resulting mass was placed in 3-

dimensional capsules of 100 mg. 

A drawing of the technological process of obtaining 

the capsule drug form of the deksketoprofen 

trametamol substance is shown in Figure 1. 

The quality indicators of finished capsules depend on 

the technological indicators of the mass. At the same 

time, the technological properties of the mass are 

affected by the added auxiliary substances and the 

technology of mass preparation. For this reason, the 

technological properties of the encapsulable mass 

were studied in the next research and compared and 

studied with these properties of the substance. The 

results obtained were presented in Table 3.

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 12-2023 11 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Table 3. 

Comparative study of Deksketoprofen trametamol substance and technical properties of capsular mass 

Identified indicator Unit of 

measure 

Deksketoprofen 

substance 

encapsulated mass 

Fractional composition: 

+1000mkm 

-1000mkm +500mkm 

-500mkm +250mkm 

-250mkm +160 mkm 

-160 mkm 

%  

2,04 

19,97 

50,42 

20,25 

7,32 

 

1.6 

20,82 

51,49 

21,31 

4,78 

scattering 10-3 kg/s 0,511 5,93 

scattering density g/sm3 0,39 0,785 

Natural deviation angle grade 62 32,5 

Residual moisture % 2,07 1,92 

Based on the given results, the technological 

properties of the encapsulable mass were more 

positive than those indicators of the deksketoprofen 

trametamol substance. In it, the smallest amount of 

the substance (2.04%) corresponded to particles larger 

than +1000 mkm and to the encapsulated mass (1.6%). 

The main part of the substance -1000 mkm +500 mkm 

(19,97%) composed of particles, it has a mass to be 

encapsulated (20.82), particles -500 mkm +250 mkm 

(50.42%) of the mass to be encapsulated (51,49) and -

250 mkm +160 mkm (20,25%) from (21.31%), substation 

(7,32%) from (4.78%) to -160 mkm consisted of small 

particles. This, in turn, shifted the dispersibility of the 

encapsulated mass in a positive direction. This index 

0,511*10-3 kg/s from increased to 5.93*10-3 kg/s. 

Similarly the scattering density of ham increased 

(0.39g/sm3 from up to 0,785 g/sm3). Deksketoprofen 

trametamol substance had a negative result of the 

angle of natural deviation (62,0 grade) and the 

encapsulated mass showed a positive result (32.5 

degrees). At the same time, it was proved that it has 

residual moisture (2.07%) to (1.97%).

 

Scheme 1. 

Technological process 

 

 

 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 12-2023 12 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

VR 1.1. Preparation of production rooms 

 

  

       

VR 1.2. Preparation of technological equipment 
 

   

       

VR 1.3. Training of production personnel 
   

    
 

VR 1. Auxiliary works 
  

VR 1.4. Preparation of raw 

materials and packaging 

materials 

  
 

Losses     

     

       

  
VR 1.5. Grinding and 

sorting of products  

   

Losses   

   

     

       

  
TR 1.1. Mixing, wet 

granulation and drying 

 

  

Losses     

     

    

 

TR 1. Preparation of the 

encapsulated mass 

TR 1.2. Granulation 
  

 

 

 
 

 

  

 
 

  

  

TR 2.1. Mass encapsulation 

   

  
 

TR 2. Encapsulation 
    

 

       

Loss 
 UMO 1.1. Capsule 

packaging 

 

  

    
 UMO 1. Packing, 

fitting and wrapping 

UMO 1.2. Equipment 
 

 
 

     Finished product 

TR 1.3. Massage 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 12-2023 13 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 12 PAGES: 6-13 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Scheme 1. The technological process of obtaining a capsule 

CONCLUSION 

The composition of the capsule drug type was selected 

and the technology was developed using the method 

of auxiliary substances and wet granulation, which 

were used in order to improve the negative 

technological properties of the capsule in the creation 

of the drug form on the basis of deksketoprofen 

trametamol substance. The technological properties of 

the substance and the encapsulated mass were 

studied in a comparative way, and the selected content 

was proven to be purposeful. This ensures that the 

quality and shelf life of the removable capsules is on 

demand. 

 

REFERENCES 

1. Koroleva I.A. Dexketoprofen – an additional ability 

to control chronic pain syndrome //Medical 

Council.-2019.-No. 10.-pp.172-178. 

2. Trukhan D.I., Bagisheva N.V., Goloshubina V.V., 

Konshu N.V. The possibilities of dexketoprofen in 

the treatment of pain syndrome at the stage of 

primary health care //Medical Sciences.-2017.-No. 

5.-pp.263-266. 

3. Krasnyuk I.I., Tarasov V.V., Kozlova Zh.M. Studying 

the influence of technological parameters of the 

mass production process for encapsulation with 

tritican – alpha //Medical and pharmaceutical 

journal “Pulse".-2019. No.10.-pp.131-137. 

4. Yunusova X.M., Jaloliddinova M.Sh. research on 

the development of the dicomz capsule 

technology // Journal of Pharmaceutics.-2018. №4.- 

S.53-55. 

5. F.X.Maksudova., M.B.Baratova., D. Sh.Tadjibaeva. 

improving the composition and technology of the 

Xind jenshen capsule// Farmasevticheskiy 

magazine.- Organizational.-2021.-№1.- S.74-78. 

6. Usmanova M.K., Maksudova F.X., Karimov O.U. 

Study of structural-mechanical and technological 

properties of dexketoprofen substance // 

Pharmaceutical Journal.- Organizational.-2022-

№5.- B.31-35. 

7. M.K.Usmanova., F.X.Maksudova. Comparative 

transformation of technological properties of 

dexketoprofen trometamol substance and 

encapsulated massapipd// "current state of the 

pharmaceutical field: attitudes and perspectives" 

(international scientific and practical conference, 

Tashkent, 2023-B.64-65. 

8. Maksudova F.H., Karieva E.S. On the issue of the 

development of intestinal soluble capsules of 

nonsteroidal anti-inflammatory action// 

Farmatsevtika jurnali.-2014.-No.4.-pp.84-89. 

9. State Pharmacopoeia Of The Republic Of 

Uzbekistan. Toskent -2021. Volume 1, part 1-2. 

10. State Pharmacopoeia of the Russian Federation, 

XIV ed., Moscow (2018); [Electronic resource], 

URL: https://femb.ru/record/pharmacopea14. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

